Cephalon — Merger or Acquisition (February 2010)
10 slides from Cephalon's merger presentation, Feb 4, 2010
Slide 1: Mepha Acquisition Conference Call February 1, 2010
Mepha Acquisition Conference Call February 1, 2010
Slide 2: Cephalon Perspective: How Does Mepha Add To Cephalon?
Cephalon Perspective How Does Mepha Add To Cephalon? Increased global reach: We can leverage our current and future products through Mepha $400 million of incremental sales: Mepha doubles the size of our international business with a sound, diverse product portfolio Increased balance: We now serve a
Slide 3: Mepha Company Profile
MEPHA Company Profile A fully integrated profitable branded generics & specialty pharmaceutical company structured around: Switzerland pharmaceutical operations International pharmaceutical operations Manufacturing & supply chain Development (pilot unit, formulation improvements) Stand-alone company
Slide 4: Estimated 2009 net sales of 408MM CHF
MEPHA Company Profile 408MM CHF estimated net sales in 2009 (approx. $400 million) Sales CAGR of 13% over the last five years Excellent complement to our existing business
Slide 5: Existing Product Portfolio
MEPHA Company Profile Existing Product Portfolio About 120 products: Improved Branded Generics (i.e. modified release) Branded generics Generics Limited Rx-OTC product range in selected countries 20 top selling products generate over 60% of 2009 sales Patented formulation technologies: Patches Gels
Slide 6: Mepha Company Profile: Innovative Dosage Forms For Better Application
Mepha Company Profile Innovative Dosage Forms For Better Application Depocaps™ - capsules filled with a number of slow-release pellets designed for a pH-independent sustained release Gastrocaps™ - enteric coated pellets protects active compounds from acidic gastric juice and ensures release in the s
Slide 7: Existing Product Portfolio
MEPHA Company Profile Existing Product Portfolio Mephaquin™ - Prophylaxis of malaria Mepharis™ - Schizophrenia Mesporin™ - Moderate to severe bacterial infections Neurorubine™ - Neuralgic pain; nerve damage due to diabetes or alcoholism Olfen™ - Acute painful inflammatory conditions Pectoral™ - Coug
Slide 8: Planned Product Launches
MEPHA Company Profile Planned Product Launches Targeting future high selling off-patent products New products in-licensed or internally-developed Close to 150 identified commercial launches planned between 2010 and 2014 (50 chemical entities) Planned product launches 34 33 34 23 28 0 10 20 30 40 201
Slide 9: Cephalon With The Addition Of Mepha
Cephalon With The Addition Of Mepha Global Bio-pharmaceutical company Sales presence in 100 countries 3,800 employees 30 percent of sales outside United States Diverse product portfolio Increasingly stable, and profitable business Deep pipeline: oncology, pain, inflammatory diseases, branded generic
Slide 10: Thank you!
{4 Cephalon Thank you! February 1, 2010